US20020127285A1 - Rhodiola and uses thereof - Google Patents
Rhodiola and uses thereof Download PDFInfo
- Publication number
- US20020127285A1 US20020127285A1 US10/139,383 US13938302A US2002127285A1 US 20020127285 A1 US20020127285 A1 US 20020127285A1 US 13938302 A US13938302 A US 13938302A US 2002127285 A1 US2002127285 A1 US 2002127285A1
- Authority
- US
- United States
- Prior art keywords
- rhodiola
- levels
- effective amount
- subject
- crenulata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001165494 Rhodiola Species 0.000 title claims abstract description 51
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 72
- 241000997135 Rhodiola crenulata Species 0.000 claims abstract description 52
- 229960003604 testosterone Drugs 0.000 claims abstract description 36
- 239000008280 blood Substances 0.000 claims abstract description 27
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 17
- 229960005309 estradiol Drugs 0.000 claims abstract description 17
- 229930182833 estradiol Natural products 0.000 claims abstract description 17
- 230000007958 sleep Effects 0.000 claims abstract description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 230000035936 sexual power Effects 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 7
- 230000009084 cardiovascular function Effects 0.000 claims abstract description 7
- 230000004217 heart function Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 42
- 230000001965 increasing effect Effects 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 206010011224 Cough Diseases 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 claims description 9
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 7
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 7
- 241000756943 Codonopsis Species 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 241000208340 Araliaceae Species 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
- 229950009148 androstenediol Drugs 0.000 claims description 4
- 235000006533 astragalus Nutrition 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 210000004233 talus Anatomy 0.000 claims description 4
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 claims description 3
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 claims description 3
- WGOUYULOZZRTFS-UHFFFAOYSA-N 5-methyl-7-methoxyisoflavone Chemical compound C=1C(OC)=CC(C)=C(C2=O)C=1OC=C2C1=CC=CC=C1 WGOUYULOZZRTFS-UHFFFAOYSA-N 0.000 claims description 3
- 241000218671 Ephedra Species 0.000 claims description 3
- 241000893536 Epimedium Species 0.000 claims description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 3
- 244000141009 Hypericum perforatum Species 0.000 claims description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- SQGZFRITSMYKRH-QAGGRKNESA-N androst-5-ene-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 SQGZFRITSMYKRH-QAGGRKNESA-N 0.000 claims description 3
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 claims description 3
- 230000036299 sexual function Effects 0.000 claims description 3
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 claims description 2
- 241000132012 Atractylodes Species 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- 240000003538 Chamaemelum nobile Species 0.000 claims description 2
- 241000050051 Chelone glabra Species 0.000 claims description 2
- 244000281702 Dioscorea villosa Species 0.000 claims description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 2
- 241000490050 Eleutherococcus Species 0.000 claims description 2
- 241001289529 Fallopia multiflora Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 claims description 2
- 244000119461 Garcinia xanthochymus Species 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 240000002045 Guettarda speciosa Species 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 2
- 244000025221 Humulus lupulus Species 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 241000244355 Ligusticum Species 0.000 claims description 2
- 241000830535 Ligustrum lucidum Species 0.000 claims description 2
- 241000234435 Lilium Species 0.000 claims description 2
- 241001106041 Lycium Species 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- 241000208343 Panax Species 0.000 claims description 2
- 235000002791 Panax Nutrition 0.000 claims description 2
- 235000011925 Passiflora alata Nutrition 0.000 claims description 2
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 2
- 240000008440 Passiflora incarnata Species 0.000 claims description 2
- 235000011922 Passiflora incarnata Nutrition 0.000 claims description 2
- 235000013750 Passiflora mixta Nutrition 0.000 claims description 2
- 235000013731 Passiflora van volxemii Nutrition 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 235000016787 Piper methysticum Nutrition 0.000 claims description 2
- 240000005546 Piper methysticum Species 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- 240000006079 Schisandra chinensis Species 0.000 claims description 2
- 241000233932 Sparganium Species 0.000 claims description 2
- 244000053655 Thunbergia mysorensis Species 0.000 claims description 2
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 2
- 244000126014 Valeriana officinalis Species 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229960004826 creatine monohydrate Drugs 0.000 claims description 2
- 235000018905 epimedium Nutrition 0.000 claims description 2
- 229940087603 grape seed extract Drugs 0.000 claims description 2
- 235000002532 grape seed extract Nutrition 0.000 claims description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 2
- 230000010490 psychological well-being Effects 0.000 claims description 2
- 235000016788 valerian Nutrition 0.000 claims description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 2
- 230000036765 blood level Effects 0.000 claims 3
- 241000190633 Cordyceps Species 0.000 claims 2
- 235000000556 Paullinia cupana Nutrition 0.000 claims 2
- 240000003444 Paullinia cupana Species 0.000 claims 2
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 claims 2
- 235000007716 Citrus aurantium Nutrition 0.000 claims 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims 1
- 240000003791 Citrus myrtifolia Species 0.000 claims 1
- 235000016646 Citrus taiwanica Nutrition 0.000 claims 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 241000735432 Hydrastis canadensis Species 0.000 claims 1
- 240000000759 Lepidium meyenii Species 0.000 claims 1
- 235000000421 Lepidium meyenii Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 235000010575 Pueraria lobata Nutrition 0.000 claims 1
- 244000046146 Pueraria lobata Species 0.000 claims 1
- 241001521901 Tribulus lanuginosus Species 0.000 claims 1
- 235000015724 Trifolium pratense Nutrition 0.000 claims 1
- 235000005679 goldenseal Nutrition 0.000 claims 1
- 235000009569 green tea Nutrition 0.000 claims 1
- 235000012902 lepidium meyenii Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- 235000020741 pine bark extract Nutrition 0.000 claims 1
- 229940106587 pine bark extract Drugs 0.000 claims 1
- 235000013526 red clover Nutrition 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- -1 algida Species 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 206010049565 Muscle fatigue Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- ZEGGZNOPAPRAIG-SPFKKGSWSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(2-methylbut-3-en-2-yloxy)oxane-3,4,5-triol Chemical compound C=CC(C)(C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZEGGZNOPAPRAIG-SPFKKGSWSA-N 0.000 description 3
- WXBBQBYCUTXTJQ-FUIZFARNSA-N 7-[(2s,3r,4r,5s,6s)-3,5-dihydroxy-6-methyl-4-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5,8-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one Chemical compound O([C@@H]1O[C@H]([C@@H]([C@@H](O[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](CO)O2)O)[C@H]1O)O)C)C(C=1O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C=C1 WXBBQBYCUTXTJQ-FUIZFARNSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003471 anti-radiation Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZEGGZNOPAPRAIG-UHFFFAOYSA-N crenulatin Natural products C=CC(C)(C)OC1OC(CO)C(O)C(O)C1O ZEGGZNOPAPRAIG-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940079877 pyrogallol Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- CIAXXTSXVCLEJK-JOEVVYSCSA-N rhodionin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1O CIAXXTSXVCLEJK-JOEVVYSCSA-N 0.000 description 3
- CIAXXTSXVCLEJK-OFXYNDJTSA-N rhodionin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)c1c(O)c2OC(c3ccc(O)cc3)=C(O)C(=O)c2c(O)c1 CIAXXTSXVCLEJK-OFXYNDJTSA-N 0.000 description 3
- WXBBQBYCUTXTJQ-WITOOHFNSA-N rhodiosin Natural products O([C@@H]1[C@H](O)[C@H](Oc2c(O)c3OC(c4ccc(O)cc4)=C(O)C(=O)c3c(O)c2)O[C@@H](C)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WXBBQBYCUTXTJQ-WITOOHFNSA-N 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BTTWKVFKBPAFDK-LOVVWNRFSA-N 4-Androstenediol Chemical compound O[C@H]1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 BTTWKVFKBPAFDK-LOVVWNRFSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CMXKUJNZWYTFJN-XFUVECHXSA-N bolandiol Chemical compound O[C@H]1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 CMXKUJNZWYTFJN-XFUVECHXSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002332 leydig cell Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000004330 tyrosol Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WELNRNVZXWUOGT-QXUSFIETSA-N (8r,9s,10r,13s,14s)-13-methyl-1,2,4,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C(=O)CC[C@@H]2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 WELNRNVZXWUOGT-QXUSFIETSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JRIZOGLBRPZBLQ-QXUSFIETSA-N 19-Norandrostenedione Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JRIZOGLBRPZBLQ-QXUSFIETSA-N 0.000 description 1
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000607305 Arctica Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001792 virilizing effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
Definitions
- the present invention relates to compositions, articles of manufacture, extracts, compounds, methods of use, methods of treatment, methods of preparation, etc., which relate to plants of the genus Rhodiola, preferably Rhodiola crenulata , which have a variety of useful and beneficial effects, including, e.g., to enhance blood oxygen and nutrients levels, e.g., through enhancing oxygen transport, to enhance working capacity and endurance, to reduce muscle fatigue, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to provide antioxidant effects, to protect against oxidation, to provide anti-cancer effects, to promote DNA repair, to provide anti-radiation effects, to protect against radiation, to reduce inflammation, to increase insulin, to decrease levels of glucagon, to reduce histamine release, to reduce allergic reactions, preferably, to modulate testosterone levels, and to modulate sleep, especially to promote sleep, to modulate blood lipids, preferably, e.g., to lower cholesterol levels, to promote weight loss, and to enhance sexuability,
- Rhodiola crenulata is a species of Rhodiola which grows mostly in China and south west of China on the altitude between 3400 meters to 5600 meters. It has been used in Vietnamese medicine for more than 1000 years for uses that have been limited to curing lung inflammation and cough, for stopping and activating blood, and for treating external wounds and burns. It has been discovered herein that Rhodiola crenulata has other beneficial properties that make it useful for a variety of conditions and diseases, as mentioned above and below.
- Rhodiola is a diverse genus of plants which includes more than 50 different species, including, e.g., algida, arctica, crenulata, elongata, gelida, imbricataishidae, iremelica, kirilowii, linearifolia, phariensis, pinnatifida, quadrifida, aff. quadrifida, rosea, sachalinensis, and wolongensis.
- chromosome number e.g., Makoto et al., Journal of Japanese Botany, 70(6):334-338, 1995
- chemical composition e.g., Makoto et al., Journal of Japanese Botany, 70(6):334-338, 1995
- chemical composition e.g., Makoto et al., Journal of Japanese Botany, 70(6):334-338, 1995
- chemical composition e.g., Makoto et al., Journal of Japanese Botany, 70(6):334-338, 1995
- chemical composition e.g., morphology, medicinal properties, developmental stages (e.g., Ishmuratatova and Satsyperova, Rasembl'nye Resursy., 34(1):3-11, 1998), geographical distribution, etc.
- Scientific studies e.g.
- Rhodiola crenulata include, e.g., salidroside, tyrosol, ⁇ -sitosterol, gallic acid, pyrogallol, crenulatin, rhodionin, rhodiosin, among which, crenulatin, e.g., is found only in R. crenulata and has not been found in any other Rhodiola species.
- Rhodiosin and rhodionin exists in some, but not all, Rhodiola species.
- plant refers to seeds, leaves, stems, flowers, roots, berries, bark, or any other plant parts that are useful for the purposes described.
- the underground portion of the plant such as the root and rhizoma
- the leaves, stems, seeds, flowers, berries, bark, or other plant parts also have medicinal effects and can be used for preparing tea and other beverages, cream, and in food preparation.
- Rhodiola of the present invention can be in any form which is effective, including, but not limited to dry powders, grounds, emulsions, extracts, and other conventional compositions.
- a suitable solvent such as water, alcohol, methanol, or any other solvents, or mixed solvents.
- the choice of the solvent can be made routinely, e.g., based on the properties of the active ingredient that is to be extracted or concentrated by the solvent.
- Rhodiola crenulata examples include, but are not limited to, salidroside, tyrosol, ⁇ -sitosterol, gallic acid, pyrogallol, crenulatin, rhodionin, and/or rhodiosin. These ingredients can be extracted in the same step, e.g., using an alcoholic solvent, or they may be extracted individually, each time using a solvent which is especially effective for extracting the particular target ingredient from the plant. In certain embodiments, extraction can be performed by the following process: Milling the selected part, preferably root, to powder. The powder can be soaked in a desired solvent for an amount of time effective to extract the active agents from the Rhodiola.
- the solution can be filtered and concentrated to produce a paste that contains a high concentration of the constituents extracted by the solvent.
- the paste can be dried to produce a powder extract of Rhodiola crenulata .
- the content of active ingredient in the extract can be measured using HPLC, UV and other spectrometry methods.
- Rhodiola of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intraarterial, and intrathecal, etc. It can be administered alone, or in combination with any ingredient(s), active or inactive, including in a medicinal form, or as a food or beverage additive.
- any effective route including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intraarterial, and intrathecal, etc. It can be administered
- Rhodiola is administered orally in any suitable form, including, e.g., whole plant, powdered or pulverized plant material, extract, pill, capsule, granule, tablet or a suspension.
- Rhodiola can be combined with any pharmaceutically acceptable carrier.
- pharmaceutically acceptable carriers any pharmaceutical carrier, such as the standard carriers described, e.g., Remington 's Pharmaceutical Science , Eighteenth Edition, Mack Publishing company, 1990.
- suitable carriers are well known in the art and can include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solutions, phosphate buffered saline containing Polysorb 80, water, emulsions such as oil/water emulsion and various type of wetting agents.
- Other carriers may also include sterile solutions, tablets, coated tablets pharmaceutical and capsules.
- Such carriers typically contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols.
- excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols.
- Such carriers can also include flavor and color additives or other ingredients.
- Compositions comprising such carriers are formulated by well known conventional methods.
- excipients formulated with Rhodiola are suitable for oral administration and do not deleteriously react with it, or other active components.
- Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose and the like.
- additives include, e.g., antioxidants and preservatives, coloring, flavoring and diluting agents, emulsifying and suspending agents, such as acacia, agar, alginic acid, sodium alginate, bentonite, carbomer, carrageenan, carboxymethylcellulose, cellulose, cholesterol, gelatin, hydroxyethyl cellulose, hydroxppropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, octoxynol 9, oleyl alcohol, povidone, propylene glycol monostearate, sodium lauryl sulfate, sorbitan esters, stearyl alcohol, tragacanth, xanthan gum, and derivatives thereof, solvents, and miscellaneous ingredients such as microcrystalline cellulose, citric acid, dextrin, dextrose, liquid glucose, lactic acid, lactose, magnesium chloride, potassium metaphosphate, starch, and the like.
- Rhodiola can also be formulated with other active ingredients, such as anti-oxidants, vitamins (A, C, ascorbic acid, B's, such as B1, thiamine, B6, pyridoxine, B complex, biotin, choline, nicotinic acid, pantothenic acid, B12, cyanocobalamin, and/or B2, D, D2, D3, calciferol, E, such as tocopherol, riboflavin, K, K1, K2).
- vitamins A, C, ascorbic acid, B's, such as B1, thiamine, B6, pyridoxine, B complex, biotin, choline, nicotinic acid, pantothenic acid, B12, cyanocobalamin, and/or B2, D, D2, D3, calciferol, E, such as tocopherol, riboflavin, K, K1, K2).
- vitamins A, C, ascorbic acid, B's, such as B1, thiamine,
- Preferred compounds include, e.g creatine monohydrate, pyruvate, L-Camitine, ⁇ -lipoic acid, Phytin or Phytic acid, Co Enzyme Q10, NADH, NAD, D-ribose, amino acids such as L-Glutamine, Lysine, chrysin; pre-hormones such as 4-drostenedione, 5-androstenedione, 4(or 5-)androstenediol, 19-nor-4 (or 5-)-drostenedione, 19-nor-4 (or 5-)-androstenediol, Beta-ecdysterone, and 5-Methyl-7-Methoxy Isoflavone.
- pre-hormones such as 4-drostenedione, 5-androstenedione, 4(or 5-)androstenediol, 19-nor-4 (or 5-)-drostenedione, 19-nor-4 (or 5-)-androstenediol
- Preferred active ingredients include, e.g., pine pollen, fructus lycii, hippophae rhamnoides, Salvia Miltiorrhiza, Ligusticum, Acanthopanax, Astragalus, Ephedra, codonopsis, polygola tenuifolia Willd, Lilium, Sparganium, ginseng, panax notogiseng, Garcinia, Guggle, Grape Seed Extract or powder, and/or Ginkgo Biloba.
- Rhodiola of the present invention includes those mentioned in various text and publications, e.g., ES Avensu, Medicinal Plants of West Africa , Reference Publications, Algonac, Mich. (1978); P. Back, The Illustrated Herbal 1987, Hamlyn Publishers, distributed by Octopus Books, Printed in Hong Kong by Mandarin, ISBN 0-600 553 361; F. Bianchini and F. Corbetta, The Fruits of the Earth, translated from Italian by A. Mancinelli, Bloomsbury Books, London, ISBN 1-870630-10-6; H. M. Burkill, The Useful plants of West Tropical Africa , Ed. 2, V.
- Other active agents include, e.g., antioxidants, anti-carcinogens, anti-inflammatory agents, hormones and hormone antagonists, antibiotics (e.g., amoxicillin) and other bacterial agents, and other medically useful drugs such as those identified in, e.g., Remington's Pharmaceutical Sciences , Eighteenth Edition, Mack Publishing Company, 1990.
- a preferred composition of the present invention comprises, about 1%-100%, preferably about 20-70% Rhodiola crenulata extract, more preferably about 60%, said extract having about 0.5-10% salidroside content; 10-45% 5:1 extracted fructus lycii powder (5 kilograms of the herb is used to produce 1 kg of herb powder); 1-20% of hippophae rhamnoides powder; and, optionally, a pharmaceutically-acceptable excipient.
- the present invention relates to methods of administering Rhodiola, especially Rhodiola crenulata , e.g., to enhance blood oxygen levels, to enhance working capacity and endurance, to reduce muscle fatigue, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to improve sexual ability, to provide antioxidant effects, to protect against oxidation, to provide anti-cancer effects, to promote DNA repair, to provide anti-radiation effects, to protect against radiation, to reduce inflammation, to increase insulin, to decrease levels of glucagon, to reduce histamine release, to reduce allergic reactions, preferably, to modulate testosterone levels, to increase male virality, to modulate sleep, especially to promote sleep. to modulate blood lipids, preferably, e.g., to lower cholesterol levels, to promote weight loss, to increase estradiol levels, etc., and other conditions and diseases as mentioned above and below.
- Rhodiola is delivered to the host in such a manner that it can achieve the desired purpose.
- Rhodiola can be administered by an effective route, such as orally, topically, rectally, etc.
- Rhodiola can be administered to any host in need of treatment, e.g., vertebrates, such as mammals, including humans, male humans, female humans, primates, pets, such as cats and dogs, livestock, such as cows, horses, birds, chickens, etc.
- Rhodiola is administered to such a host.
- Effective amounts are such amounts which are useful to achieve the desired effect, preferably a beneficial or therapeutic effect as described above.
- Such amount can be determined routinely, e.g., by performing a dose-response experiment in which varying doses are administered to cells, tissues, animal models (such as rats or mice in maze-testing, swimming tests, toxicity tests, memory tests as performed by standard psychological testing, etc.) to determine an effective amount in achieving an effect.
- Amounts are selected based on various factors, including the milieu to which the virus is administered (e.g., a patient with cancer, animal model, tissue culture cells, etc.), the site of the cells to be treated, the age, health, gender, and weight of a patient or animal to be treated, etc.
- Useful amounts include, 10 milligrams-100 grams, preferably, e.g., 100 milligrams-10 grams, 250 milligrams-2.5 grams, 1 gm, 2 gm, 3 gm, 500 milligrams-1.25 grams. etc., per dosage of different forms of Rhodiola crenulata such as the herbal powder, herbal extract paste or powder, tea and beverages prepared to contain the effective ingredients of Rhodiola, injections, depending upon the need of the recipients and the method of preparation.
- the present invention relates to a method of increasing testosterone levels in a host in need thereof, comprising, administering an effective amount of a Rhodiola to said host.
- Testosterone principal male hormone, or androgen
- Testosterone is produced mainly in the Leydig cells in the male testes.
- the Leydig cells also produce two other androgens of less potency and in much smaller quantities.
- Testosterone stimulates the development of the male secondary sex characteristics after puberty, causing growth of the beard and pubic hair, development of the penis, and change of voice.
- the hormone also aids in growth, muscular development, and masculine body contour of the adult male.
- Testosterone is considered to be a male virilizing hormone. Its effects include maintenance of muscle and bone mass, improving and/or enhancing sexual function and psychological well being among others. As males grow older, especially after the age of 35, a slow decline in testosterone levels is observed which is accompanied by symptoms that have been associated with the condition known as “andropause”. Symptoms of andropause include lethargy, depression, lack of sexual desire and function, and loss of muscle mass and strength. Increasing testosterone levels therefore can be useful to treat any of the mentioned conditions. Additionally, increasing testosterone levels can be useful in treating certain types of breast cancer in women.
- Testosterone levels refer to the amounts of testosterone which are circulating in the blood, e.g., as measured using enzyme-linked immunosorbent assay, HPLC, or any other suitable detection method.
- Rhodiola crenulata Any effective amount of Rhodiola crenulata can be administered.
- a standardized Rhodiola crenulata extract e.g., having 0.1-110%. preferably 1-6%) salidroside by total weight of composition
- intake of a standardized Rhodiola crenulata extract e.g., having 0.1-110%. preferably 1-6%) salidroside by total weight of composition
- a standardized Rhodiola crenulata extract e.g., having 0.1-110%. preferably 1-6%) salidroside by total weight of composition
- subjects showed about a 76% increase in total testosterone in the blood as compared to the 6.0% increase in total testosterone level after taking placebo for a month.
- These amounts can be increased by any value, e.g., at least about 5%, 10%, 15%, 20%, 50%, 60% 70%, 75%, 100%, 2-fold, 5-fold, etc., over amounts which are present in the blood prior to
- the present invention also relates to a method of increasing estradiol levels in a host in need thereof, comprising, administering an effective amount of a Rhodiola to said host.
- Estradiol is a female sex hormone that stimulates the appearance of secondary female sex characteristics in girls at puberty. Estradiol controls growth of the lining of the uterus during the first part of the menstrual cycle, cause changes in the breast during pregnancy, and regulate various metabolic processes. Increasing estradiol can treat various conditions, including menopausal symptoms, estrogen deficiencies in women (most commonly after menopause; low eight; etc) and inflammation of the vagina. It can also stimulate lactation following childbirth and in the treatment, but not cure, advanced and even disseminated cancer of the prostate gland in men.
- Amounts of estradiol can be increased by any value, e.g., 5%, 6%, 8%, 10%, 15%, 20%, 30%, 50%, 75%, 100%, 2-fold, 5-fold, etc., over amounts which are present in the blood prior to administration.
- Rhodiola as effective in increasing estradiol levels by about 12% as compared to only 3% in controls.
- Rhodiola can used to treat conditions associated with estrogen deficiency, such as menopuse, perimenopause, low-weight, etc.
- Rhodiola can be combined with any agent which raises testosterone and/or estradiol levels.
- testosterone precursors such as those disclosed in U.S. Pat. Nos. 5,880,117 and 6,011,027, e.g., 4-androstenediol and 19-nor-4-androstenediol, can be utilized in combination with Rhodiola as a means of increasing testosterone levels in human.
- Rhodiola crenulata can also be formulated to boost hormonal levels with other herbs, such as wild yam, Epimedium (including all Epimedium species), Angelica, Lycium, panex ginseng, Ganoderma lucidum , Codonopsis, Eleutherococcus, Schisandra chinensis , Atractylodes, and Ligustrum lucidum.
- other herbs such as wild yam, Epimedium (including all Epimedium species), Angelica, Lycium, panex ginseng, Ganoderma lucidum , Codonopsis, Eleutherococcus, Schisandra chinensis , Atractylodes, and Ligustrum lucidum.
- the present invention also relates methods of improving sleep in a host in need thereof, comprising administering an effective amount of a Rhodiola to said host.
- a beneficial effect on sleep including, e.g., prolonging sleep time (e.g., as measured in animal models by administering Rhodiola in the presence or absence of a barbiturate, or other sleep-promoting agent, and determining the sleep-prolongation time produced by Rhodiola), increasing time spent in REM-sleep, reducing sleep apnea and other sleep disorders, decreasing insomnia, decreasing amount of time to fall asleep, etc.
- Rhodiola can also be formulated with other agents which promote sleep, such as Valerian, Melatonin, Kava Kava, St. John's Wort, Tryptophan and 5-Hydroxytryptophan, Astragalus, Hops, Passionflower, Skullcap, Chamomile, He Shou Wu, Ashwaganda, and Lady's Slipper.
- agents which promote sleep such as Valerian, Melatonin, Kava Kava, St. John's Wort, Tryptophan and 5-Hydroxytryptophan, Astragalus, Hops, Passionflower, Skullcap, Chamomile, He Shou Wu, Ashwaganda, and Lady's Slipper.
- the present invention also relates to methods of treating impotence, comprising administering an effective amount of Rhodiola, preferable Rhodiola crenulata .
- Impotency, or erectile dysfunction is the inability to achieve an erection.
- the ability of Rhodiola crenulata to increase the blood oxygen transportation and testosterone level can enhance male sexual ability and performance in some cases.
- the Rhodiola can be administered immediately prior to performance, or more preferably, on a daily basis according to the regime mentioned above to increase testosterone levels.
- Rhodiola can also be administered in combination with agents which are used for treating impotency, including, e.g., vasodilators, phosphodiesterase inhibitors, stimulators of NO release, alpha-adrenergic agents, etc.
- Rhodiola crenulata can also be used to enhance blood oxygen levels and transport to body tissues; to enhance working capacity and endurance.
- working capacity and endurance it preferably meant that the effective amount increases the ability to perform a physical task, such as in exercise, physical labor, or sports activity, even before fatigue would normally occur; thus, enhanced working capacity and endurance is defined herein not to mean “fatigue,” which simply indicates that the performer does not tire.
- Associated with enhanced working capacity and endurance can be an increase in muscle ATP levels and a reduction in circulating lactic acid levels (see, Examples 2 and 3).
- the present invention also relates to methods of increasing muscle ATP levels and/or reducing lactic acid in blood, thereby enhancing working capacity and endurance, improving sexual performance, etc.
- Rhodiola crenulata reduces blood lactic acid (lactate) levels. Such reduction in lactic acid levels indicates that muscle fatigue is reduced.
- muscle fatigue it is meant that the muscle cells carry out anaerobic respiration because of lack of oxygen. Reducing muscle fatigue therefore means, e.g., that fewer muscle cells become anaerobic.
- the present invention therefore also relates to a method of reducing muscle fatigue comprising administering an effective amount of Rhodiola crenulata . Lactic acid can be reduced by an effective amount in ameliorating fatigue, such as at least 10%, 15%, 20 %, 25 %, 30 %, 35 %, etc.
- Rhodiola crenulata increases the ATP available to muscle, e.g., by increasing aerobic respiration, by increasing oxygen transport, etc. Amounts of ATP can be increased by an effective amount in reducing muscle fatigue, such as 20%, 25%, 30%, 35%, 37%, 40%, 40%, 45%, 50%, etc.
- Rhodiola can also be used to enhance or improved memory and concentration (such improved functions are to be distinguished from the more general brain stimulation which indicates increased non-selective neuronal activity, whereas the mentioned improved functions are selective, e.g., by stimulating specific parts of the brain or other organs, or by stimulating specific neural and hormonal systems); to reduce stress, e.g., lower blood pressure, reduce anxiety, promote calmness; to enhance cardiac and cardiovascular function (including, e.g., to protect against heart disease); to provide antioxidant effects and protect against oxidation; to provide anti-cancer effects, e.g., promote cessation of cell growth; to promote DNA repair; to provide anti-radiation effects and to protect against radiation, e.g., as a sun-screen when applied topically to the skin; to reduce inflammation, e.g., systemic inflammation, skin inflammation (where Rhodiola can be administered topically), but with the proviso that it is not lung-inflammation, coughing, or bleeding associated with lung-inflammation and coughing
- mice 10 males and 10 females, weighing approximately 18-22 grams each, were randomly divided into experimental and control groups, with each group containing 10 mice.
- Mice in the experimental group were provided with food containing about 50 mg (0.05 gram, about 0.25 gram every 1 kilogram body weight) Rhodiola crenulata per day for 3 days.
- Mice in the control group were fed with the same food but without Rhodiola crenulata.
- mice After 3 days of consuming food containing Rhodiola crenulata , the mice were subjected to a swimming test. A lead weight that comprised about 6% of the mice's body weight was attached to each mouse prior to placing it in a water-filled receptacle. The average survival time for experimental group was 92.85 ⁇ 5.20 minutes while for the control group it was 69.89 ⁇ 5.10 minutes. This represents a 33% improvement in the endurance of mice fed Rhodiola crenulata as compared to controls.
- test groups 40 volunteers are divided into two groups, each comprising 20 people.
- the test group was administered 2 grams of Rhodiola crenulata standardized extract (with 2% salidroside), once a day for one month.
- the control group received a placebo. After one month, each participant was required to assess improvement of their memory, sleep, physical strength, and sexual performance. Blood samples were collected prior to taking any Rhodiola and after the one-month period.
- test subjects were asked whether their memory was improved during the course of the test. In the test group, 45% stated that their memory was improved after one month of the medication. In the control group, only 21% reported memory improvement after one month of the placebo.
- test subjects were asked whether their physical strength was improved. In the test group, 81% reported improvements in physical strength after one month of the medication as compared to only 38% in the control group.
- Test subjects were asked whether their sexual performance was improved. In the test group, 75% described improved sexual performance after one month of the Rhodiola extract. In the control group, only 28.9% said their sexual performance was improved.
- Test subjects were asked whether their sleep is improved. In the test group, 83% of the subjects their sleep was improved after one month of the Rhodiola. In the control group, 41% said their sleep is improved after one month medication.
- the blood testosterone levels of each participant was tested.
- the average of testosterone level of the test group before and after taking Rhodiola crenulata , once a day, for a month was 17.68 ⁇ 5.6 mmol/L and 31.12 ⁇ 10.6 mmol/L, respectively.
- the average testosterone level before and after taking placebo for a month was 18.02 ⁇ 6.0 mmol/L and 19.10 ⁇ 7.6 mmol/L respectively.
- the Rhodiola increased testosterone levels by 76%, while in controls the increase was only 6%.
- a composition comprising effective amounts of Rhodiola crenulata can be administered to subjects to enhance levels of blood oxygen, to enhance working capacity and endurance, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to provide antioxidant effects, to modulate testosterone levels, to modulate sleep, and to improve sexual performance. to increase energy level, and to enhance memory and concentration.
- a composition can comprise, by weight:
Abstract
The present invention relates to Rhodiola, preferably Rhodiola crenulata, to treat various conditions and diseases in mammals. Rhodiola crenulata is a Tibetan herb which has been discovered to have highly useful and beneficial properties heretofore unknown. Rhodiola crenulata is especially preferred to enhance blood oxygen levels, to enhance working capacity and endurance, to enhance memory and concentration, to enhance cardiac and cardiovascular function, to provide antioxidant effects, to protect against oxidation, to modulate testosterone and estradiol levels, to modulate sleep, and to enhance sexuability, such as improve sexual performance.
Description
- The present invention relates to compositions, articles of manufacture, extracts, compounds, methods of use, methods of treatment, methods of preparation, etc., which relate to plants of the genus Rhodiola, preferablyRhodiola crenulata, which have a variety of useful and beneficial effects, including, e.g., to enhance blood oxygen and nutrients levels, e.g., through enhancing oxygen transport, to enhance working capacity and endurance, to reduce muscle fatigue, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to provide antioxidant effects, to protect against oxidation, to provide anti-cancer effects, to promote DNA repair, to provide anti-radiation effects, to protect against radiation, to reduce inflammation, to increase insulin, to decrease levels of glucagon, to reduce histamine release, to reduce allergic reactions, preferably, to modulate testosterone levels, and to modulate sleep, especially to promote sleep, to modulate blood lipids, preferably, e.g., to lower cholesterol levels, to promote weight loss, and to enhance sexuability, such as improve sexual performance.
-
- Rhodiola is a diverse genus of plants which includes more than 50 different species, including, e.g., algida, arctica, crenulata, elongata, gelida, imbricataishidae, iremelica, kirilowii, linearifolia, phariensis, pinnatifida, quadrifida, aff. quadrifida, rosea, sachalinensis, and wolongensis. These species vary from each other widely, differing in, e.g., chromosome number (e.g., Makoto et al.,Journal of Japanese Botany, 70(6):334-338, 1995), chemical composition, morphology, medicinal properties, developmental stages (e.g., Ishmuratatova and Satsyperova, Rastitel'nye Resursy., 34(1):3-11, 1998), geographical distribution, etc. Scientific studies (e.g. Peng et al, Chinese Herb Medicine(1995), 26(4): 177-179, and Wang et al, Acta Phrmaceutica Sinica(1992), 27(2): 117-120) indicate constituents of Rhodiola crenulata include, e.g., salidroside, tyrosol, β-sitosterol, gallic acid, pyrogallol, crenulatin, rhodionin, rhodiosin, among which, crenulatin, e.g., is found only in R. crenulata and has not been found in any other Rhodiola species. Rhodiosin and rhodionin exists in some, but not all, Rhodiola species.
- The term “plant” as used herein refers to seeds, leaves, stems, flowers, roots, berries, bark, or any other plant parts that are useful for the purposes described. For certain uses, it is preferred that the underground portion of the plant, such as the root and rhizoma, be utilized. The leaves, stems, seeds, flowers, berries, bark, or other plant parts, also have medicinal effects and can be used for preparing tea and other beverages, cream, and in food preparation.
- Rhodiola of the present invention can be in any form which is effective, including, but not limited to dry powders, grounds, emulsions, extracts, and other conventional compositions. To extract or concentrate the effective ingredients of Rhodiola, typically the plant part is contacted with a suitable solvent, such as water, alcohol, methanol, or any other solvents, or mixed solvents. The choice of the solvent can be made routinely, e.g., based on the properties of the active ingredient that is to be extracted or concentrated by the solvent. Preferred active ingredients ofRhodiola crenulata include, but are not limited to, salidroside, tyrosol, β-sitosterol, gallic acid, pyrogallol, crenulatin, rhodionin, and/or rhodiosin. These ingredients can be extracted in the same step, e.g., using an alcoholic solvent, or they may be extracted individually, each time using a solvent which is especially effective for extracting the particular target ingredient from the plant. In certain embodiments, extraction can be performed by the following process: Milling the selected part, preferably root, to powder. The powder can be soaked in a desired solvent for an amount of time effective to extract the active agents from the Rhodiola. The solution can be filtered and concentrated to produce a paste that contains a high concentration of the constituents extracted by the solvent. In some cases, the paste can be dried to produce a powder extract of Rhodiola crenulata. The content of active ingredient in the extract can be measured using HPLC, UV and other spectrometry methods.
- A Rhodiola of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intraarterial, and intrathecal, etc. It can be administered alone, or in combination with any ingredient(s), active or inactive, including in a medicinal form, or as a food or beverage additive.
- In preferred embodiments of the invention, Rhodiola is administered orally in any suitable form, including, e.g., whole plant, powdered or pulverized plant material, extract, pill, capsule, granule, tablet or a suspension.
- Rhodiola can be combined with any pharmaceutically acceptable carrier. By the phrase, “pharmaceutically acceptable carriers,” it is meant any pharmaceutical carrier, such as the standard carriers described, e.g.,Remington 's Pharmaceutical Science, Eighteenth Edition, Mack Publishing company, 1990. Examples of suitable carriers are well known in the art and can include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solutions, phosphate buffered saline containing Polysorb 80, water, emulsions such as oil/water emulsion and various type of wetting agents. Other carriers may also include sterile solutions, tablets, coated tablets pharmaceutical and capsules. Typically such carriers contain excipients such as such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols. Such carriers can also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods. Generally excipients formulated with Rhodiola are suitable for oral administration and do not deleteriously react with it, or other active components.
- Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose and the like. Other additives include, e.g., antioxidants and preservatives, coloring, flavoring and diluting agents, emulsifying and suspending agents, such as acacia, agar, alginic acid, sodium alginate, bentonite, carbomer, carrageenan, carboxymethylcellulose, cellulose, cholesterol, gelatin, hydroxyethyl cellulose, hydroxppropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, octoxynol 9, oleyl alcohol, povidone, propylene glycol monostearate, sodium lauryl sulfate, sorbitan esters, stearyl alcohol, tragacanth, xanthan gum, and derivatives thereof, solvents, and miscellaneous ingredients such as microcrystalline cellulose, citric acid, dextrin, dextrose, liquid glucose, lactic acid, lactose, magnesium chloride, potassium metaphosphate, starch, and the like.
- Rhodiola can also be formulated with other active ingredients, such as anti-oxidants, vitamins (A, C, ascorbic acid, B's, such as B1, thiamine, B6, pyridoxine, B complex, biotin, choline, nicotinic acid, pantothenic acid, B12, cyanocobalamin, and/or B2, D, D2, D3, calciferol, E, such as tocopherol, riboflavin, K, K1, K2). Preferred compounds, include, e.g creatine monohydrate, pyruvate, L-Camitine, α-lipoic acid, Phytin or Phytic acid, Co Enzyme Q10, NADH, NAD, D-ribose, amino acids such as L-Glutamine, Lysine, chrysin; pre-hormones such as 4-drostenedione, 5-androstenedione, 4(or 5-)androstenediol, 19-nor-4 (or 5-)-drostenedione, 19-nor-4 (or 5-)-androstenediol, Beta-ecdysterone, and 5-Methyl-7-Methoxy Isoflavone. Preferred active ingredients include, e.g., pine pollen, fructus lycii, hippophae rhamnoides, Salvia Miltiorrhiza, Ligusticum, Acanthopanax, Astragalus, Ephedra, codonopsis, polygola tenuifolia Willd, Lilium, Sparganium, ginseng, panax notogiseng, Garcinia, Guggle, Grape Seed Extract or powder, and/or Ginkgo Biloba.
- Other plants and herbs which can be formulated with a Rhodiola of the present invention includes those mentioned in various text and publications, e.g.,ES Avensu, Medicinal Plants of West Africa, Reference Publications, Algonac, Mich. (1978); P. Back, The Illustrated Herbal 1987, Hamlyn Publishers, distributed by Octopus Books, Printed in Hong Kong by Mandarin, ISBN 0-600 553 361; F. Bianchini and F. Corbetta, The Fruits of the Earth, translated from Italian by A. Mancinelli, Bloomsbury Books, London, ISBN 1-870630-10-6; H. M. Burkill, The Useful plants of West Tropical Africa, Ed. 2, V. I, Royal Botanic Gardens Kew, ISBN 0-947643-01-X (1985); L. Boulos, Medicinal Plants of North Africa, Reference Publications Inc., Algonac, Mich. (1983); and N. C. Shah, Herbal Folk Medicines in Northern India, J. Ethnopharm, 6:294-295 (1982).
- Other active agents include, e.g., antioxidants, anti-carcinogens, anti-inflammatory agents, hormones and hormone antagonists, antibiotics (e.g., amoxicillin) and other bacterial agents, and other medically useful drugs such as those identified in, e.g.,Remington's Pharmaceutical Sciences, Eighteenth Edition, Mack Publishing Company, 1990. A preferred composition of the present invention comprises, about 1%-100%, preferably about 20-70% Rhodiola crenulata extract, more preferably about 60%, said extract having about 0.5-10% salidroside content; 10-45% 5:1 extracted fructus lycii powder (5 kilograms of the herb is used to produce 1 kg of herb powder); 1-20% of hippophae rhamnoides powder; and, optionally, a pharmaceutically-acceptable excipient.
- The present invention relates to methods of administering Rhodiola, especiallyRhodiola crenulata, e.g., to enhance blood oxygen levels, to enhance working capacity and endurance, to reduce muscle fatigue, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to improve sexual ability, to provide antioxidant effects, to protect against oxidation, to provide anti-cancer effects, to promote DNA repair, to provide anti-radiation effects, to protect against radiation, to reduce inflammation, to increase insulin, to decrease levels of glucagon, to reduce histamine release, to reduce allergic reactions, preferably, to modulate testosterone levels, to increase male virality, to modulate sleep, especially to promote sleep. to modulate blood lipids, preferably, e.g., to lower cholesterol levels, to promote weight loss, to increase estradiol levels, etc., and other conditions and diseases as mentioned above and below.
- By the term “administering,” it is meant that Rhodiola is delivered to the host in such a manner that it can achieve the desired purpose. As mentioned Rhodiola can be administered by an effective route, such as orally, topically, rectally, etc. Rhodiola can be administered to any host in need of treatment, e.g., vertebrates, such as mammals, including humans, male humans, female humans, primates, pets, such as cats and dogs, livestock, such as cows, horses, birds, chickens, etc.
- An effective amount of Rhodiola is administered to such a host. Effective amounts are such amounts which are useful to achieve the desired effect, preferably a beneficial or therapeutic effect as described above. Such amount can be determined routinely, e.g., by performing a dose-response experiment in which varying doses are administered to cells, tissues, animal models (such as rats or mice in maze-testing, swimming tests, toxicity tests, memory tests as performed by standard psychological testing, etc.) to determine an effective amount in achieving an effect. Amounts are selected based on various factors, including the milieu to which the virus is administered (e.g., a patient with cancer, animal model, tissue culture cells, etc.), the site of the cells to be treated, the age, health, gender, and weight of a patient or animal to be treated, etc. Useful amounts include, 10 milligrams-100 grams, preferably, e.g., 100 milligrams-10 grams, 250 milligrams-2.5 grams, 1 gm, 2 gm, 3 gm, 500 milligrams-1.25 grams. etc., per dosage of different forms ofRhodiola crenulata such as the herbal powder, herbal extract paste or powder, tea and beverages prepared to contain the effective ingredients of Rhodiola, injections, depending upon the need of the recipients and the method of preparation.
- In preferred embodiments, the present invention relates to a method of increasing testosterone levels in a host in need thereof, comprising, administering an effective amount of a Rhodiola to said host. Testosterone, principal male hormone, or androgen, is produced mainly in the Leydig cells in the male testes. The Leydig cells also produce two other androgens of less potency and in much smaller quantities. Testosterone stimulates the development of the male secondary sex characteristics after puberty, causing growth of the beard and pubic hair, development of the penis, and change of voice. The hormone also aids in growth, muscular development, and masculine body contour of the adult male.
- Testosterone is considered to be a male virilizing hormone. Its effects include maintenance of muscle and bone mass, improving and/or enhancing sexual function and psychological well being among others. As males grow older, especially after the age of 35, a slow decline in testosterone levels is observed which is accompanied by symptoms that have been associated with the condition known as “andropause”. Symptoms of andropause include lethargy, depression, lack of sexual desire and function, and loss of muscle mass and strength. Increasing testosterone levels therefore can be useful to treat any of the mentioned conditions. Additionally, increasing testosterone levels can be useful in treating certain types of breast cancer in women.
- Testosterone levels refer to the amounts of testosterone which are circulating in the blood, e.g., as measured using enzyme-linked immunosorbent assay, HPLC, or any other suitable detection method.
- Any effective amount ofRhodiola crenulata can be administered. In accordance with present invention, it has been demonstrated that intake of a standardized Rhodiola crenulata extract (e.g., having 0.1-110%. preferably 1-6%) salidroside by total weight of composition) produced a significant increase in total testosterone as compared to placebo. For example, after taking 2 grams of standardized rhodiola extract with 2% salidroside, once a day for a month, subjects showed about a 76% increase in total testosterone in the blood as compared to the 6.0% increase in total testosterone level after taking placebo for a month. These amounts, however, can be increased by any value, e.g., at least about 5%, 10%, 15%, 20%, 50%, 60% 70%, 75%, 100%, 2-fold, 5-fold, etc., over amounts which are present in the blood prior to administration.
- The present invention also relates to a method of increasing estradiol levels in a host in need thereof, comprising, administering an effective amount of a Rhodiola to said host.
- Estradiol is a female sex hormone that stimulates the appearance of secondary female sex characteristics in girls at puberty. Estradiol controls growth of the lining of the uterus during the first part of the menstrual cycle, cause changes in the breast during pregnancy, and regulate various metabolic processes. Increasing estradiol can treat various conditions, including menopausal symptoms, estrogen deficiencies in women (most commonly after menopause; low eight; etc) and inflammation of the vagina. It can also stimulate lactation following childbirth and in the treatment, but not cure, advanced and even disseminated cancer of the prostate gland in men. Amounts of estradiol can be increased by any value, e.g., 5%, 6%, 8%, 10%, 15%, 20%, 30%, 50%, 75%, 100%, 2-fold, 5-fold, etc., over amounts which are present in the blood prior to administration. For example, in Example 10, Rhodiola as effective in increasing estradiol levels by about 12% as compared to only 3% in controls. Thus, Rhodiola can used to treat conditions associated with estrogen deficiency, such as menopuse, perimenopause, low-weight, etc.
- Rhodiola can be combined with any agent which raises testosterone and/or estradiol levels. For example, testosterone precursors, such as those disclosed in U.S. Pat. Nos. 5,880,117 and 6,011,027, e.g., 4-androstenediol and 19-nor-4-androstenediol, can be utilized in combination with Rhodiola as a means of increasing testosterone levels in human. Currently, 4-androstenedione, 5-androstenedione, 4-androstenediol, 5-androstenediol, 19-nor4-androstenedione, 19-nor-5-androstenedione, 19-nor-4-androstenediol, and 19-nor-5androstenediol, Beta-ecdysterone, and 5-Methyl-7-Methoxy Isoflavone are being used to increase the testosterone level in humans.Rhodiola crenulata can be used with these ingredients to enhance their effects of boosting the testosterone level, other hormones, such as estradiol. Rhodiola crenulata can also be formulated to boost hormonal levels with other herbs, such as wild yam, Epimedium (including all Epimedium species), Angelica, Lycium, panex ginseng, Ganoderma lucidum, Codonopsis, Eleutherococcus, Schisandra chinensis, Atractylodes, and Ligustrum lucidum.
- The present invention also relates methods of improving sleep in a host in need thereof, comprising administering an effective amount of a Rhodiola to said host. By the phrase “improving sleep,” it meant bringing about a beneficial effect on sleep, including, e.g., prolonging sleep time (e.g., as measured in animal models by administering Rhodiola in the presence or absence of a barbiturate, or other sleep-promoting agent, and determining the sleep-prolongation time produced by Rhodiola), increasing time spent in REM-sleep, reducing sleep apnea and other sleep disorders, decreasing insomnia, decreasing amount of time to fall asleep, etc.
- Rhodiola can also be formulated with other agents which promote sleep, such as Valerian, Melatonin, Kava Kava, St. John's Wort, Tryptophan and 5-Hydroxytryptophan, Astragalus, Hops, Passionflower, Skullcap, Chamomile, He Shou Wu, Ashwaganda, and Lady's Slipper.
- The present invention also relates to methods of treating impotence, comprising administering an effective amount of Rhodiola, preferableRhodiola crenulata. Impotency, or erectile dysfunction, is the inability to achieve an erection. The ability of Rhodiola crenulata to increase the blood oxygen transportation and testosterone level can enhance male sexual ability and performance in some cases. The Rhodiola can be administered immediately prior to performance, or more preferably, on a daily basis according to the regime mentioned above to increase testosterone levels. Rhodiola can also be administered in combination with agents which are used for treating impotency, including, e.g., vasodilators, phosphodiesterase inhibitors, stimulators of NO release, alpha-adrenergic agents, etc.
- Administration ofRhodiola crenulata can also be used to enhance blood oxygen levels and transport to body tissues; to enhance working capacity and endurance. By “working capacity and endurance,” it preferably meant that the effective amount increases the ability to perform a physical task, such as in exercise, physical labor, or sports activity, even before fatigue would normally occur; thus, enhanced working capacity and endurance is defined herein not to mean “fatigue,” which simply indicates that the performer does not tire. Associated with enhanced working capacity and endurance can be an increase in muscle ATP levels and a reduction in circulating lactic acid levels (see, Examples 2 and 3). Thus, the present invention also relates to methods of increasing muscle ATP levels and/or reducing lactic acid in blood, thereby enhancing working capacity and endurance, improving sexual performance, etc.
- As shown in the Example 2,Rhodiola crenulata reduces blood lactic acid (lactate) levels. Such reduction in lactic acid levels indicates that muscle fatigue is reduced. By “muscle fatigue,” it is meant that the muscle cells carry out anaerobic respiration because of lack of oxygen. Reducing muscle fatigue therefore means, e.g., that fewer muscle cells become anaerobic. The present invention therefore also relates to a method of reducing muscle fatigue comprising administering an effective amount of Rhodiola crenulata. Lactic acid can be reduced by an effective amount in ameliorating fatigue, such as at least 10%, 15%,20%,25%,30%,35%, etc.
- As shown in Example 3,Rhodiola crenulata increases the ATP available to muscle, e.g., by increasing aerobic respiration, by increasing oxygen transport, etc. Amounts of ATP can be increased by an effective amount in reducing muscle fatigue, such as 20%, 25%, 30%, 35%, 37%, 40%, 40%, 45%, 50%, etc.
- Rhodiola can also be used to enhance or improved memory and concentration (such improved functions are to be distinguished from the more general brain stimulation which indicates increased non-selective neuronal activity, whereas the mentioned improved functions are selective, e.g., by stimulating specific parts of the brain or other organs, or by stimulating specific neural and hormonal systems); to reduce stress, e.g., lower blood pressure, reduce anxiety, promote calmness; to enhance cardiac and cardiovascular function (including, e.g., to protect against heart disease); to provide antioxidant effects and protect against oxidation; to provide anti-cancer effects, e.g., promote cessation of cell growth; to promote DNA repair; to provide anti-radiation effects and to protect against radiation, e.g., as a sun-screen when applied topically to the skin; to reduce inflammation, e.g., systemic inflammation, skin inflammation (where Rhodiola can be administered topically), but with the proviso that it is not lung-inflammation, coughing, or bleeding associated with lung-inflammation and coughing, to increase insulin, to decrease levels of glucagon, to reduce histamine release, to reduce allergic reactions, to enhance sexual ability.Rhodiola crenulata in accordance with the present invention is preferably not used to treat external wounds, external burns, lung inflammation, and coughing.
- Method of Examples One, Two, and Three
- 20 Kunming-species mice (10 males and 10 females), weighing approximately 18-22 grams each, were randomly divided into experimental and control groups, with each group containing 10 mice. Mice in the experimental group were provided with food containing about 50 mg (0.05 gram, about 0.25 gram every 1 kilogram body weight) Rhodiola crenulata per day for 3 days. Mice in the control group were fed with the same food but withoutRhodiola crenulata.
- Example One
- After 3 days of consuming food containingRhodiola crenulata, the mice were subjected to a swimming test. A lead weight that comprised about 6% of the mice's body weight was attached to each mouse prior to placing it in a water-filled receptacle. The average survival time for experimental group was 92.85±5.20 minutes while for the control group it was 69.89±5.10 minutes. This represents a 33% improvement in the endurance of mice fed Rhodiola crenulata as compared to controls.
- Example Two
- After one hour of swimming, the blood lactate levels were assayed as a measure of fatigue. The average blood lactate level for the experimental group was 14.50±1.41 mmol/L while the control group was 19.30±1.80 mmol/L. Thus, muscle fatigue levels were reduced by 25% in mice fedRhodiola crenulata.
- Example Three
- After one hour of swimming, the levels of skeletal muscle ATP level were measured. The average skeletal ATP level for the experimental group was 210.45±14.88 mg/100 g while for the control group it was 153.88±20.67 mg/100 g. ATP levels were increased by 37% in mice fedRhodiola crenulata, indicating that the herb enhanced energy levels.
- Method for Example Four, Five, Six, Seven, Eight, Nine, Ten, Eleven
- 40 volunteers are divided into two groups, each comprising 20 people. The test group was administered 2 grams ofRhodiola crenulata standardized extract (with 2% salidroside), once a day for one month. The control group received a placebo. After one month, each participant was required to assess improvement of their memory, sleep, physical strength, and sexual performance. Blood samples were collected prior to taking any Rhodiola and after the one-month period.
- Example Four
- Using a blood oxygen analyzer, the blood oxygen pressure of each participant before and after takingRhodiola crenulata extract and placebo was tested. The average of the blood oxygen pressure of the test group before and after taking Rhodiola crenulata for a month was 6.97±0.64 and 7.86±0.90 respectively. For the control group, the average testosterone level before and after taking placebo for a month was 6.87±0.66 and is 7.04±0.95 respectively. These results show after taking Rhodiola crenulata for one month, the oxygen transport and supply in the human body is enhanced by about 12.6%.
- Example Five
- The test subjects were asked whether their memory was improved during the course of the test. In the test group, 45% stated that their memory was improved after one month of the medication. In the control group, only 21% reported memory improvement after one month of the placebo.
- Example Six
- The test subjects were asked whether their physical strength was improved. In the test group, 81% reported improvements in physical strength after one month of the medication as compared to only 38% in the control group.
- Example Seven
- Test subjects were asked whether their sexual performance was improved. In the test group, 75% described improved sexual performance after one month of the Rhodiola extract. In the control group, only 28.9% said their sexual performance was improved.
- Example Eight
- Test subjects were asked whether their sleep is improved. In the test group, 83% of the subjects their sleep was improved after one month of the Rhodiola. In the control group, 41% said their sleep is improved after one month medication.
- Example Nine
- Using an enzyme-linked immunosorbent assay, the blood testosterone levels of each participant was tested. The average of testosterone level of the test group before and after takingRhodiola crenulata, once a day, for a month was 17.68±5.6 mmol/L and 31.12±10.6 mmol/L, respectively. For the control group, the average testosterone level before and after taking placebo for a month was 18.02±6.0 mmol/L and 19.10±7.6 mmol/L respectively. The Rhodiola increased testosterone levels by 76%, while in controls the increase was only 6%.
- Example Ten
- Using an enzyme-linked immunosorbent assay, the blood estradiol levels of each participant before and after takingRhodiola crenulata extract and placebo were tested. The average of estradiol level of the test group before and after taking Rhodiola crenulata for a month was 163.56±33.9 mmo/L and 182.93±107.34 mmol/L respectively. For the control group, the average estradiol level before and after taking placebo for a month was 164.5±34.43 mmol/L and 169.30±40.02 mmol/L respectively. Rhodiola increased estradiol levels by about 12% whereas in control the increase was only about 3%.
- Example Eleven
- The blood content of superoxide dismutase (SOD) levels of each participant was tested using the method of pyrogallol auto-oxidization before and after taking Rhodiola crenulata extract and placebo. The average of SOD level of the test group before and after takingRhodiola crenulata for a month was 1173.8±122.2 U/g.Hb and 1296.7±157.3 U/g.Hb respectively. For the comparison group, the average testosterone level before and after taking placebo for a month was 1173.4±121.5 U/g.Hb and 1205.8±147.40 U/g.Hb respectively. This test indicates that Rhodiola crenulata has antioxidant effects.
- Example Twelve
- A composition comprising effective amounts ofRhodiola crenulata can be administered to subjects to enhance levels of blood oxygen, to enhance working capacity and endurance, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to provide antioxidant effects, to modulate testosterone levels, to modulate sleep, and to improve sexual performance. to increase energy level, and to enhance memory and concentration. Such a composition can comprise, by weight:
- 60%Rhodiola crenulata, having 2% salidroside content; and
- 30% of a 5:1 extracted fructus lycii powder; and
- 10% of hippophae rhamnoides powder.
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limiting the remainder of the disclosure in any way whatsoever. The entire disclosure of all applications, patents and publications, cited above and in the figures are hereby incorporated by reference in their entirety.
Claims (29)
1. A method of increasing testosterone levels in a subject in need thereof, comprising, administering an effective amount of a Rhodiola to said subject.
2. A method of claim 1 , with the proviso that said subjects do not have lung inflammation, coughing, or an external wound or burn.
3. A method of claim 1 , wherein said testosterone levels are raised by at least 10%.
4. A method of claim 1 , wherein said testosterone levels are raised by at least 15%.
5. A method of claim 1 , wherein said Rhodiola is Rhodiola crenulata.
6. A method of claim 2 , wherein said Rhodiola is an extract which comprises 2% salidroside by weight.
7. A method of claim 1 , wherein said increase in testosterone level is effective in enhancing sexual performance, maintaining muscle and bone mass, and improving sexual function and psychological well being.
8. A method of treating estrogen deficiency in a female human subject in need thereof, comprising administering an effective amount of Rhodiola to said subject, whereby said amount is effective in increasing blood estradiol levels.
9. A method of claim 8 , with the proviso that said subjects do not have lung inflammation, coughing, or an external wound or burn.
10. A method of claim 8 , wherein said estrodiol levels are increased by at least 10%.
11. A method of claim 9 , wherein said subject is menopausal.
12 A method of improving sleep in a subject in need thereof, comprising, administering an effective amount of a Rhodiola to said subject.
13. A method of claim 12 , with the proviso that said subjects do not have lung inflammation, coughing, or an external wound or burn.
14 A method of claim 13 , wherein said Rhodiola is Rhodiola crenulata.
15. A method of enhancing transport of blood oxygen, enhancing working capacity and endurance, or enhancing cardiac and cardiovascular function in a subject in need thereof, comprising,
administering an effective amount of a Rhodiola crenulata to said subject, whereby said amount of Rhodiola is effective to reduce blood levels of lactate.
16. A method of claim 15 , wherein said amount of Rhodiola is effective to raise skeletal levels of ATP.
17. A method of claim 15 , wherein the skeletal levels of ATP are raised at least 30%.
18. Am method of claim 15 , wherein blood levels of lactate are reduced at least 20%.
19. A method of claim 15 , with the proviso that said subjects do not have lung inflammation, coughing, or an external wound or burn.
20. A method of enhancing memory and concentration in a subject in need thereof, comprising,
administering an effective amount of a Rhodiola crenulata to said subject.
21. A method of claim 20, with the proviso that said subjects do not have lung inflammation, coughing, or an external wound or burn.
administering an effective amount of a Rhodiola crenulata to said subject.
23. A method of claim 20, with the proviso that said subjects are do not have lung inflammation, coughing, or an external wound or burn.
24. A method of claim 22, wherein blood levels of lactate are reduced at least 20%.
25. A method of claim 1 , wherein said composition for increasing hormonal levels of testosterone or estradiol, comprising
an effective amount of Rhodiola crenulata, and
an effective amount of an herb selected from wild yam, Epimedium, Angelica, Lycium, panex ginseng, Ganoderma lucidum, Codonopsis, Eleutherococcus, fructus lycii, hippophae rhamnoides, Schisandra chinensis, Atractylodes, Yohimbe, Tribulus Terrestris, Guggle, Guarana, Cordyceps, Codonopsis, maca, or Ligustrum lucidum.
26. A method of claim 1 , wherein said composition for increasing hormonal levels of testosterone or estradiol, comprising
an effective amount of Rhodiola crenulata, and
an effective amount 4-drostenedione, 5-androstenedione, 4(or 5-)androstenediol, 19nor-4 (or 5-)-drostenedione, 19-nor-4 (or 5-)-androstenediol, Beta-ecdysterone, and 5-Methyl-7-Methoxy Isoflavone.
27. A method of claim 12 , wherein said composition for enhancing sleep, comprising
an effective amount of Rhodiola crenulata, and
an effective amount of an agent selected from Valerian, Melatonina, Kava Kava, St. John's Wort, Trytophan and 5-Hydroxytryptophan, Astragalus, Hops, Passionflower, Skullcap, Chamomile, He Shou Wu, Ashwaganda, fructus lycii, hippophae rhamnoides, or Lady's Slipper.
28. An herbal composition comprising:
an amount of Rhodiola crenulata, and
an amount of a herb selected from pine pollen, fructus lycii, hippophae rhamnoides, Salvia Miltiorrhiza, Ligusticum, Acanthopanax, Astragalus, Ephedra, codonopsis, polygola tenuifolia Willd, Lilium, Guggle, Kudzu, red clover, pine bark extract, St.
John's Wort, Green tea, Yohimbe, Rehmania, Hawthorn, Guarana, Goldenseal, Fo-ti, Ephedra, Dong Quai, Cordyceps, Codonopsis, Citrus Aurantium, Sparganium, ginseng, panax notogiseng, Garcinia, Guggle, Grape Seed Extract or powder, Ginkgo Biloba., Creatine Monohydrate, D-Ribose, Pyruvate, NADH, Co-enzyme Q10, Camitine, or Conjuagated Linoleic Acid.
29. A composition of claim 28, comprising:
20-70% Rhodiola crenulata extract, said extract having 0.5-10% salidroside content,
10-45% 5:1 extracted fructus lycii powder;
1-20% of hippophae rhamnoides powder; and, optionally,
a pharmaceutically-acceptable excipient.
30. An herbal composition of claim 28,
wherein said composition is effective to enhance levels of blood oxygen, to enhance working capacity and endurance, to enhance memory and concentration, to reduce stress, to enhance cardiac and cardiovascular function, to provide antioxidant effects, to modulate testosterone levels, to modulate sleep, to improve sexual performance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/139,383 US20020127285A1 (en) | 2000-04-28 | 2002-05-07 | Rhodiola and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/559,830 US6399116B1 (en) | 2000-04-28 | 2000-04-28 | Rhodiola and used thereof |
US10/139,383 US20020127285A1 (en) | 2000-04-28 | 2002-05-07 | Rhodiola and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/559,830 Division US6399116B1 (en) | 2000-04-28 | 2000-04-28 | Rhodiola and used thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020127285A1 true US20020127285A1 (en) | 2002-09-12 |
Family
ID=24235199
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/559,830 Expired - Fee Related US6399116B1 (en) | 2000-04-28 | 2000-04-28 | Rhodiola and used thereof |
US10/139,383 Abandoned US20020127285A1 (en) | 2000-04-28 | 2002-05-07 | Rhodiola and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/559,830 Expired - Fee Related US6399116B1 (en) | 2000-04-28 | 2000-04-28 | Rhodiola and used thereof |
Country Status (1)
Country | Link |
---|---|
US (2) | US6399116B1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050002992A1 (en) * | 2003-06-17 | 2005-01-06 | Mccleary Edward Larry | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
US20050031718A1 (en) * | 2003-04-10 | 2005-02-10 | Pharmanex, Llc | Sea Buckthorn compositions and associated methods |
GB2405335A (en) * | 2003-08-28 | 2005-03-02 | Coletica | Use of Rhodiola crenulata extract via the topical route |
US20050048136A1 (en) * | 2003-08-27 | 2005-03-03 | Choudhry Muhammad S. | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness |
US20050202104A1 (en) * | 2002-09-28 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Method of enhancement of cognitive skills |
WO2005115426A1 (en) * | 2004-05-31 | 2005-12-08 | Wakunaga Pharmaceutical Co., Ltd. | Drug for ameliorating male climacteric disorder |
US20060002871A1 (en) * | 2004-06-30 | 2006-01-05 | Goldstein Mindy S | Cosmetic compositions and methods comprising rhodiola rosea |
US20060198872A1 (en) * | 2005-03-07 | 2006-09-07 | Chioma Ikonte | Plant based dietary supplement for improving the duration and quality of sleep |
JP2006306889A (en) * | 2004-05-31 | 2006-11-09 | Wakunaga Pharmaceut Co Ltd | Drug for ameliorating male climacteric disorder |
US20060269623A1 (en) * | 2005-05-31 | 2006-11-30 | Pierre Swaab | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men |
JP2007084559A (en) * | 2004-05-31 | 2007-04-05 | Wakunaga Pharmaceut Co Ltd | Blood testosterone level-lowering inhibitor |
US20070196348A1 (en) * | 2006-02-23 | 2007-08-23 | Gardiner Paul T | Compositions and methods for the induction and maintenance of quality sleep |
WO2008051170A2 (en) * | 2006-10-24 | 2008-05-02 | Daniska Vladimir | Beverage with energizing effects |
KR100848213B1 (en) | 2007-03-23 | 2008-07-24 | 주식회사한국신약 | Tribulus terrestris l. extract having growth hormone secretion accelerating function |
CN100417333C (en) * | 2004-08-12 | 2008-09-10 | 薛惠芳 | Forage additive for increasing egg yield and preventing hens from peaking each other |
CN100448446C (en) * | 2005-08-16 | 2009-01-07 | 水利部沙棘开发管理中心 | Buckthorn extract, its preparing method and use in pharmaceutical process |
US20090274783A1 (en) * | 2008-04-17 | 2009-11-05 | Integrated Chinese Medicine Holdings Ltd. | Herbal compositions and methods for enhancing vital energy and athletic performance |
US20090317497A1 (en) * | 2006-04-20 | 2009-12-24 | Wen Hsien Chou | Compositions and methods for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
WO2010140832A3 (en) * | 2009-06-04 | 2011-04-14 | 안국약품 주식회사 | Pharmaceutical composition containing herbal extracts for preventing or treating nephritis |
US20120128832A1 (en) * | 2010-11-22 | 2012-05-24 | Smith Rogelio A | Organic vegan protein shakes |
US20120177623A1 (en) * | 2011-01-10 | 2012-07-12 | Morteza Naghavi | Compositions for Boosting Metabolism, Assisting Weight Loss, and Promoting Cardiovascular Health |
CN102648964A (en) * | 2011-02-28 | 2012-08-29 | 王春玉 | Medicine for treating headache, hypertension and cardiovascular and cerebrovascular disease |
WO2013016636A1 (en) * | 2011-07-27 | 2013-01-31 | Max International, Llc | Compositions comprising sugar-cysteine products |
CN103110741A (en) * | 2012-12-22 | 2013-05-22 | 潘海燕 | Medicinal liquor for treating stomach illness |
CN103127276A (en) * | 2011-11-29 | 2013-06-05 | 北京清美联创干细胞科技有限公司 | Anti-aging health care preparation by promoting proliferation and differentiation in stem cells |
CN103565929A (en) * | 2013-11-21 | 2014-02-12 | 王大娟 | Traditional Chinese medicine combination for treating heart blood deficiency type night sweat |
CN104224885A (en) * | 2014-09-11 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicine composition for relieving physical fatigue |
CN104970371A (en) * | 2015-07-02 | 2015-10-14 | 湖南炎帝生物工程有限公司 | Health-care food with antioxidant function |
US9700589B2 (en) * | 2015-02-03 | 2017-07-11 | Naturex Sa | Compositions and methods for improved muscle metabolism |
CN107551141A (en) * | 2017-10-24 | 2018-01-09 | 张永 | A kind of Wen Yang consolidates Chinese medicine tea-drinking of resisting cold and preparation method thereof |
CN107691736A (en) * | 2017-09-29 | 2018-02-16 | 武汉华士特工业生物技术开发有限公司 | A kind of maca pollen grains candy and preparation method thereof |
US10967024B2 (en) | 2018-09-26 | 2021-04-06 | Aretha Duncan | Synergistic herbal stimulant compositions |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6908614B2 (en) * | 1999-10-12 | 2005-06-21 | Chee-Keung Chung | Anti-aging/menopause symptoms relief using ganoderma lucidum spores |
US6485758B2 (en) * | 2000-02-18 | 2002-11-26 | Vasolabs, Inc. | Hangover treatment |
KR100439209B1 (en) * | 2001-03-30 | 2004-07-07 | 남종현 | Natural tea for improving stamina and preparing method thereof |
US20030069203A1 (en) * | 2001-06-04 | 2003-04-10 | Lee Steve S. | Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate |
KR100680121B1 (en) * | 2001-08-09 | 2007-02-07 | 데구사 푸드 인그리디언츠 게엠베하 | Formulation containing lyso-phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
EP1425026B1 (en) * | 2001-09-14 | 2010-05-05 | Max Zeller Söhne AG | Valeriana officinalis extract for treating sleep-induced apnea or hypopnea |
US6905706B2 (en) * | 2002-04-16 | 2005-06-14 | Swedish Herbal Institute | Medicinal herbal extract carpediol for treating depression |
ITRM20020620A1 (en) * | 2002-12-13 | 2004-06-14 | Sigma Tau Ind Farmaceuti | USE OF CARNITINE FOR THE PREVENTION AND / OR TREATMENT OF DISORDERS CAUSED BY ANDROPAUSE. |
US7776913B2 (en) * | 2002-12-13 | 2010-08-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Carnitines for treating or preventing disorders caused by andropause |
JP5300195B2 (en) * | 2003-09-08 | 2013-09-25 | ジェニオウス バイオメド インターナショナル インコーポレイテッド | Composition of botanical extract for cancer treatment |
US20050214394A1 (en) * | 2003-09-22 | 2005-09-29 | James Dao | Hippophae rhamnoides compositions for cancer therapy |
US20060024339A1 (en) * | 2004-07-29 | 2006-02-02 | Howard Murad | Methods of managing the redness associated with a dermatological condition |
TR201818697T4 (en) * | 2004-11-16 | 2019-01-21 | Dsm Ip Assets Bv | Use of antioxidant compounds for muscle damage. |
WO2006122274A2 (en) * | 2005-05-11 | 2006-11-16 | Baystate Health Systems, Inc. | Pharmaceutical formulations of rhodiola crenulata and methods of use thereof |
KR20090064398A (en) * | 2006-10-05 | 2009-06-18 | 디에스엠 아이피 어셋츠 비.브이. | Olive extracts for promoting muscle health |
WO2008127302A2 (en) * | 2006-10-27 | 2008-10-23 | Genyous BioMed International, Inc. | Compositions for treatment and inhibition of pain |
US7794758B2 (en) * | 2007-04-05 | 2010-09-14 | Pmc Formulas, Inc. | Compounds and methods for promoting cellular health and treatment of cancer |
US8394425B2 (en) * | 2007-04-05 | 2013-03-12 | Pmc Formulas, Inc. | Methods for promoting cellular health and treatment of cancer |
US20110097427A1 (en) * | 2009-10-27 | 2011-04-28 | Shyam Ramakrishnan | Molecular Targets and Dietary Modulators of Exercise-Induced Muscle Damage |
EP2753350A4 (en) | 2011-09-06 | 2015-02-18 | Bing Lou Wong | Oral delivery for hemoglobin based oxygen carriers |
US9763889B2 (en) | 2015-06-29 | 2017-09-19 | Billion King International Ltd. | Oral delivery system for hemoglobin based oxygen carriers |
US10052290B2 (en) | 2016-02-04 | 2018-08-21 | Billion King International Ltd. | Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers |
CN110643582B (en) * | 2019-09-29 | 2021-07-27 | 浙江工业大学 | Method for extracting SOD from fresh sea-buckthorn fruit |
CN116139157B (en) * | 2023-04-19 | 2023-07-04 | 中国农业大学 | Application of salidroside in promoting growth and development of ovarian follicles and preparing ovulation promoting medicine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1138984A (en) * | 1995-06-26 | 1997-01-01 | 军事医学科学院放射医学研究所 | Anti-thrombosis glucoside medicine |
-
2000
- 2000-04-28 US US09/559,830 patent/US6399116B1/en not_active Expired - Fee Related
-
2002
- 2002-05-07 US US10/139,383 patent/US20020127285A1/en not_active Abandoned
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202104A1 (en) * | 2002-09-28 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Method of enhancement of cognitive skills |
US20050031718A1 (en) * | 2003-04-10 | 2005-02-10 | Pharmanex, Llc | Sea Buckthorn compositions and associated methods |
US20060263459A1 (en) * | 2003-04-10 | 2006-11-23 | Pharmanex, Llc | Sea Buckthorn Compositions and Associated Methods |
US20050002992A1 (en) * | 2003-06-17 | 2005-01-06 | Mccleary Edward Larry | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
US20050048136A1 (en) * | 2003-08-27 | 2005-03-03 | Choudhry Muhammad S. | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness |
US20050048138A1 (en) * | 2003-08-28 | 2005-03-03 | Coletica | Use of Rhodiola crenulata extract via the topical route |
US20120107425A1 (en) * | 2003-08-28 | 2012-05-03 | Eric Perrier | Use of rhodiola crenulata extract via the topical route |
GB2405335A (en) * | 2003-08-28 | 2005-03-02 | Coletica | Use of Rhodiola crenulata extract via the topical route |
FR2859102A1 (en) * | 2003-08-28 | 2005-03-04 | Coletica | USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC |
GB2405335B (en) * | 2003-08-28 | 2006-03-08 | Coletica | Use of rhodiola crenulata extract via the topical route |
US20080274213A1 (en) * | 2004-05-31 | 2008-11-06 | Wakunaga Pharmaceutical Co., Ltd. | Drug for Ameliorating Male Climacteric Disorders |
JP2006306889A (en) * | 2004-05-31 | 2006-11-09 | Wakunaga Pharmaceut Co Ltd | Drug for ameliorating male climacteric disorder |
JP2007084559A (en) * | 2004-05-31 | 2007-04-05 | Wakunaga Pharmaceut Co Ltd | Blood testosterone level-lowering inhibitor |
WO2005115426A1 (en) * | 2004-05-31 | 2005-12-08 | Wakunaga Pharmaceutical Co., Ltd. | Drug for ameliorating male climacteric disorder |
US20100297042A1 (en) * | 2004-06-30 | 2010-11-25 | Goldstein Mindy S | Cosmetic Compositions and Methods Comprising Rhodiola Rosea |
US7449203B2 (en) | 2004-06-30 | 2008-11-11 | E-L Management Corporation | Cosmetic compositions and methods comprising Rhodiola rosea |
US20060002871A1 (en) * | 2004-06-30 | 2006-01-05 | Goldstein Mindy S | Cosmetic compositions and methods comprising rhodiola rosea |
US20080268074A1 (en) * | 2004-06-30 | 2008-10-30 | Goldstein Mindy S | Cosmetic Compositions and Methods Comprising Rhodiola Rosea |
CN100417333C (en) * | 2004-08-12 | 2008-09-10 | 薛惠芳 | Forage additive for increasing egg yield and preventing hens from peaking each other |
US20060275520A1 (en) * | 2005-03-07 | 2006-12-07 | Access Business Group International Llc | White peony extract for improving the duration and quality of sleep |
US20060198872A1 (en) * | 2005-03-07 | 2006-09-07 | Chioma Ikonte | Plant based dietary supplement for improving the duration and quality of sleep |
US20060269623A1 (en) * | 2005-05-31 | 2006-11-30 | Pierre Swaab | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men |
CN100448446C (en) * | 2005-08-16 | 2009-01-07 | 水利部沙棘开发管理中心 | Buckthorn extract, its preparing method and use in pharmaceutical process |
US7914826B2 (en) * | 2006-02-23 | 2011-03-29 | Iomedix Sleep International Srl | Method for promoting sleep |
US7906154B2 (en) * | 2006-02-23 | 2011-03-15 | Heuer Marvin A | Compositions and methods for the induction and maintenance of quality sleep |
US20070264337A1 (en) * | 2006-02-23 | 2007-11-15 | Gardiner Paul T | Compositions and methods for the induction and maintenance of quality sleep |
US20070196348A1 (en) * | 2006-02-23 | 2007-08-23 | Gardiner Paul T | Compositions and methods for the induction and maintenance of quality sleep |
US20090011015A1 (en) * | 2006-02-23 | 2009-01-08 | Iomedix Sleep International | Method for promoting sleep |
US7476405B2 (en) * | 2006-02-23 | 2009-01-13 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
US20090317497A1 (en) * | 2006-04-20 | 2009-12-24 | Wen Hsien Chou | Compositions and methods for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
WO2008051170A3 (en) * | 2006-10-24 | 2008-09-04 | Vladimir Daniska | Beverage with energizing effects |
WO2008051170A2 (en) * | 2006-10-24 | 2008-05-02 | Daniska Vladimir | Beverage with energizing effects |
US20100062112A1 (en) * | 2006-10-24 | 2010-03-11 | Daniska Vladimir | Beverage with energizing effects |
KR100848213B1 (en) | 2007-03-23 | 2008-07-24 | 주식회사한국신약 | Tribulus terrestris l. extract having growth hormone secretion accelerating function |
US20090274783A1 (en) * | 2008-04-17 | 2009-11-05 | Integrated Chinese Medicine Holdings Ltd. | Herbal compositions and methods for enhancing vital energy and athletic performance |
US7906159B2 (en) * | 2008-04-17 | 2011-03-15 | Vivien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
US20110091585A1 (en) * | 2008-04-17 | 2011-04-21 | Integrated Chinese Medicine Holdings Ltd. | Herbal compositions and methods for enhancing vital energy and athletic performance |
US8119170B2 (en) * | 2008-04-17 | 2012-02-21 | Wen Hsien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
US8642096B2 (en) | 2009-06-04 | 2014-02-04 | Ahn-Gook Pharmaceutical Co., Ltd. | Pharmaceutical composition containing herbal extract for prevention or treatment of nephritis |
WO2010140832A3 (en) * | 2009-06-04 | 2011-04-14 | 안국약품 주식회사 | Pharmaceutical composition containing herbal extracts for preventing or treating nephritis |
CN102497874A (en) * | 2009-06-04 | 2012-06-13 | 韩国安国药品株式会社 | Pharmaceutical composition containing herbal extracts for preventing or treating nephritis |
US20120128832A1 (en) * | 2010-11-22 | 2012-05-24 | Smith Rogelio A | Organic vegan protein shakes |
US8815310B2 (en) * | 2011-01-10 | 2014-08-26 | Morteza Naghavi | Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health |
US20120177623A1 (en) * | 2011-01-10 | 2012-07-12 | Morteza Naghavi | Compositions for Boosting Metabolism, Assisting Weight Loss, and Promoting Cardiovascular Health |
CN102648964A (en) * | 2011-02-28 | 2012-08-29 | 王春玉 | Medicine for treating headache, hypertension and cardiovascular and cerebrovascular disease |
WO2013016636A1 (en) * | 2011-07-27 | 2013-01-31 | Max International, Llc | Compositions comprising sugar-cysteine products |
CN103127276A (en) * | 2011-11-29 | 2013-06-05 | 北京清美联创干细胞科技有限公司 | Anti-aging health care preparation by promoting proliferation and differentiation in stem cells |
CN103110741A (en) * | 2012-12-22 | 2013-05-22 | 潘海燕 | Medicinal liquor for treating stomach illness |
CN103565929A (en) * | 2013-11-21 | 2014-02-12 | 王大娟 | Traditional Chinese medicine combination for treating heart blood deficiency type night sweat |
CN104224885A (en) * | 2014-09-11 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicine composition for relieving physical fatigue |
US9700589B2 (en) * | 2015-02-03 | 2017-07-11 | Naturex Sa | Compositions and methods for improved muscle metabolism |
CN107624069A (en) * | 2015-02-03 | 2018-01-23 | 纳图瑞克斯有限公司 | For improving the composition and method of muscle metabolism |
CN104970371A (en) * | 2015-07-02 | 2015-10-14 | 湖南炎帝生物工程有限公司 | Health-care food with antioxidant function |
CN107691736A (en) * | 2017-09-29 | 2018-02-16 | 武汉华士特工业生物技术开发有限公司 | A kind of maca pollen grains candy and preparation method thereof |
CN107551141A (en) * | 2017-10-24 | 2018-01-09 | 张永 | A kind of Wen Yang consolidates Chinese medicine tea-drinking of resisting cold and preparation method thereof |
US10967024B2 (en) | 2018-09-26 | 2021-04-06 | Aretha Duncan | Synergistic herbal stimulant compositions |
Also Published As
Publication number | Publication date |
---|---|
US6399116B1 (en) | 2002-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6399116B1 (en) | Rhodiola and used thereof | |
US6277396B1 (en) | Dietary supplement containing a thermogenic substance and an adrenal support substance | |
US20210220422A1 (en) | Dietary supplement compositions and methods | |
US20120141601A1 (en) | Dietary supplement, feed and pharmaceutical composition containing chia seed and maca, and preparation method thereof | |
US7338672B2 (en) | Herbal supplement for cognitive related impairment due to estrogen loss | |
US20010006983A1 (en) | Multicomponent biological vehicle | |
CN102697035A (en) | Cordyceps anti-aging pellet | |
CN104256600A (en) | Health care nutritional composition, preparation method and application thereof | |
CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
Al-Mashhadani et al. | Effect of supplementing different levels of chamomile oil on broiler performance and some physiological traits | |
WO2018112475A1 (en) | Energy compositions and methods | |
US20070184127A1 (en) | Herbal compositions comprising Portaluca | |
CN112843154A (en) | Blood-enriching hair-growing composition | |
US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
Pundkar et al. | A review: Herbal therapy used in hair loss | |
CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
CN106692532A (en) | Traditional Chinese medicine composition used for burning fat and losing weight as well as patch and weight losing package thereof | |
Carnevale et al. | Griffonia simplicifolia negatively affects sexual behavior in female rats | |
CN112869160B (en) | Freckle removing composition containing folic acid and preparation method thereof | |
CN102091228A (en) | Medicine for treating insomnia and preparation method thereof | |
CN101933968A (en) | Pharmaceutical composition with functions of resisting oxidation and delaying senility and preparation method thereof | |
CN101828703B (en) | Product for enhancing organic immunity and improving sleeping quality and preparation method thereof | |
CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
CN104644651A (en) | Applications of 20(R)-ginsenoside Rg3 in preparation of anti-aging drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |